Using Dynamic Incentives to Encourage Abstinence in a Drug Epidemic
How to cite
Dizon-Ross, Rebecca; Zucker, Ariel; Waite, Mindy. 2021. "Using Dynamic Incentives to Encourage Abstinence in a Drug Epidemic." AEA RCT Registry. AEARCTR-0008314. https://doi.org/10.1257/rct.8314-1.2000000000000002
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
Combatting the rise of the opioid epidemic is a central challenge of U.S. health care policy. A promising approach for improving welfare and decreasing medical costs of people with substance abuse disorders is offering incentive payments for healthy behaviors. This approach, broadly known as “contingency management” in the medical literature, has repeatedly shown to be effective in treating substance abuse.
However, the use of incentives by treatment facilities remains extremely low. Furthermore, it is not well understood how to design optimal incentives to treat opioid abuse. This project will conduct a randomized evaluation of two types of dynamically adjusting incentive schedules for people with opioid use disorders or cocaine use disorders: “escalating” schedules where incentive amounts increase with success to increase
incentive power, and “de-escalating” schedules where incentive amounts decrease with success to improve incentive targeting. Both schemes are implemented with a novel “turnkey” mobile application, making them uniquely low-cost, low-hassle, and scalable. Effects will be measured on abstinence outcomes, including longest duration of abstinence and the percentage of negative drug tests. In combination with survey data,
variation from the experiment will shed light on the barriers to abstinence more broadly and inform our understanding of optimal incentive design.
Intervention
Our primary intervention is a 12-week incentives intervention which provides participants with incentives for abstaining from drug use. Participants will be registered for a mobile app provided by DynamiCare Health and a provided with linked debit card. The app will prompt patients to submit saliva drug tests through their mobile phones on a random schedule (averaging three tests per week). For these randomly scheduled “contingent” tests, patients will receive immediate financial rewards in exchange for submitting drug-negative samples.
Within the intervention group, we will randomize six total incentive schedules: both a “High” and “Low” version of Escalating, De-escalating, and constant incentives. The schedules are designed so that both High schedules will pay similar amounts on average, as will both Low schedules.
• Escalating Groups, High and Low: In the Escalating groups, incentive amounts increase with every negative drug test up to a ceiling, and “reset” to the lowest amount when a test is positive or missed. Incentives in the High group will range from $4-$16, and $2-$8 in the Low group.
• De-escalating Groups, High and Low: In the De-escalating groups, incentive amounts increase with every positive or missed drug test (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). Incentives in the High group will range from $10-$20, and $6-$12 in the Low group.
• Constant Groups, High and Low: In the constant groups
Experimental design
We enroll adults adults with cocaine or opioid use disorders in urban Wisconsin. We begin with a one-week induction period, during which all patients will be registered for a mobile app provided by DynamiCare health and asked to complete an initial “non-contingent” saliva drug test. Patients who submit a first test will then be randomly assigned to one of our intervention groups, or to a control group that simply receives outpatient treatment as usual, for a 12-week intervention period. During this time, the intervention groups will receive their assigned intervention and the control group will receive treatment as usual. For all participants, the mobile app provided by DynamiCare Health will prompt remote “non-contingent follow-up” saliva drug tests every four weeks (including at the 12 week mark), which will be rewarded with $20 gift cards, to monitor abstinence behavior for study purposes. We will also conduct an endline survey with all participants at the end of the 12-week period.
Design details
Cited by
No citation data available for this registration yet.